Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NOTE 8 - RESTATEMENT - LONG TERM DEBT
'The Company has taken loan from Emry Capital before 2008. The North Carolina Company ignored the inclusion of debt of $500,000 which has now been restated in 2016 by increasing accumulated deficits and long term loans. This loan includes two notes amounting to $500,000 and one for $94,000. Together with interest it now amounts to $1,000,000 being interest rate of 12% per annum.
This is the first time that I have seen this reported for new entity.
Anyone know if it is still valid and what the conversion rate would be if they cannot or choose to not pay the 12% interest payments? Thank you Stockvaper
Thank you for that article. You have consistently done some good research on this industry as i clicked on your latest posts up to 10 screens back and learned alot about this particular industry. Very few articles list competing companies to get an idea on potential market share or stock price, do you have any opinion on this. Thank you again!
Tjainlv,
I appreciate all of your insight on this stock, especially concerning the need and capabilities of their product(s) for your industry. Have you discussed with the CEO how big the market opportunity might be, never mind what percentage they (LDSR) hope to go after? I believe you were the first to bring up the importance of the opportunity below! I am really looking forward to this major event.
https://www.otcmarkets.com/stock/LDSR/news/DATA443-OTCPK-LDSR-ClassiDocs-Invited-to-2018-RSA-Conference-Early-Stage-Expo?id=187196
DATA443 (OTCPK: LDSR) ClassiDocs Invited to 2018 RSA Conference Early Stage ExpoPress Release | 03/26/2018
RALEIGH, N.C., March 26, 2018 (GLOBE NEWSWIRE) -- DATA443 Risk Mitigation, Inc., a leading data security company that is actively developing and acquiring cybersecurity, blockchain products and Data Privacy Compliance products - has been invited to exhibit at the RSA Conference Early Stage Expo for its award winning GDPR Compliance, Data Classification and Governance product – ClassiDocs.
“GDPR, Data Privacy and International data transfers across borders continue to be front page news. We have been preparing for this opportunity and look forward to announcing our latest products at the conference. The Early Stage Expo is a perfect opportunity to showcase our continuing market leading advantage in Data Classification, Governance and GDPR Compliance solutions.” said Jason Remillard, CEO & President of Data443...
I see that Genethera finally announced some serious financing:
https://www.sec.gov/Archives/edgar/data/1017110/000101711018000003/0001017110-18-000003-index.htm
"On November 20, 2017, the Company entered into a Stock Purchase Agreement in the amount of $250,000 for Preferred A Stock, as the first payment based on the Letter of Intent, which was executed on November 30, 2017.
On November 30, 2017, the Company entered into a Non-Binding Letter of Intent for $5,000,000 from an unrelated entity. On December 13, 2017, the Stock Purchase Agreement was finalized with the $250,000 investment with the Company. The Milestones are as follows: The initial investment was provided at the Sign of The Letter of Intent in the amount of $250,000; the Second Milestone entails for the Company to Finalize Lease Agreement in collaboration with GTI Research, Inc. to a Fully Operational Level, Complete GeneThera Financial Statement for the Form 10-Q period ending September 30, 2016 and file it with the Securities Exchange Commission on or before March 31, 2018 in the amount of $300,000. The third Milestone must cover GeneThera’s Regain of Full Compliance with the SEC Financial Requirements in the amount of $1,200,000; the Fourth Milestone covers the Design Assembly and Validation of Advanced Robotic System in the amount of $1,500,000 and the Sixth Milestone entails to Enter into an Agreement with Government Organization and/or Private Company."
Looking at their website, which may be out of date, it looks they are still focusing on food safety...even though there are other potential lucrative opportunities out there for their proprietary testing technologies, ie. look at the article that I previously posted!
http://www.genethera.net/en/index.php,
Any idea how Acadia's presentation was received at the annual Needham Healthcare Conference?
"ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the 17th Annual Needham Healthcare Conference on Tuesday, March 27, 2018, at 11:30 a.m. Eastern Time in New York City."
CJake1,
What or whom is "DEAD here"? The stock, the company or just managements ability to get financing?
How effective would Genethera technology be in testing blood for
Walgreens? Seems like a huge opportunity!
http://www.nytimes.com/2016/07/09/business/theranos-elizabeth-holmes-ban.html?src=me&_r=0
United States regulators have banned Elizabeth Holmes, the chief executive of Theranos, from owning or operating a medical laboratory for at least two years, in a major setback for the embattled blood-testing start-up and its once widely lauded founder.
In a statement late Thursday, Theranos said the regulators revoked the certification of its Newark, Calif., laboratory and prohibited the laboratory from taking Medicare and Medicaid payments for its services. Regulators also levied a monetary penalty that Theranos did not specify. The sanctions take effect in 60 days, Theranos said.
Theranos represents the promise and the pitfalls of the start-up era, as money floods into young companies with new technologies in an effort to find a “unicorn” — a billion-dollar business that transforms its industry and makes its backers rich in the process. The high-profile start-up rose to prominence on the promise that it could detect health ailments by testing blood drawn cheaply by the mere prick of a finger.
The government scrutiny stemmed from questions about the effectiveness of Theranos’s technology and the way it operates its labs. Authorities who reviewed its practices last year found that all 81 patient results they inspected were inaccurate in a test of blood clotting administered from April to September on patients who take the blood thinner warfarin.
What Theranos and Ms. Holmes will do next is not clear. Lab operators have the right to appeal a canceled certification. Reached via email, an outside spokesman for the company declined to comment.
“We accept full responsibility for the issues at our laboratory in Newark, Calif., and have already worked to undertake comprehensive remedial actions,” Ms. Holmes said in a statement.
Theranos and its young founder in particular offered a compelling narrative in the crowded start-up universe: a brilliant college dropout with an audacious idea that would upend the medical testing business. Ms. Holmes invited comparisons to the Apple co-founder Steve Jobs because of her youth, her tight control of the company she founded and even her customary black turtleneck sweaters.
Ms. Holmes began the company in 2003 after dropping out of Stanford University at the age of 19. Her goal was to create a new way to perform blood tests that relied on a few drops of blood rather than the larger amounts medical testing often requires. Tests would be cheaper, the argument went, and more people would be inclined to get them. In interviews focused on Theranos’s success, she said the idea came from her fear of needles.
The idea had appeal. Theranos won backing from tech luminaries like the software mogul Larry Ellison, while the company counted Henry Kissinger, the former secretary of state, and the former Senate majority leader Bill Frist among its advisers. It also struck a deal with Walgreens, the drugstore chain, to perform tests. By last year, the company had assembled an eminent board of directors and commanded a valuation of about $9 billion.
But some people questioned the reliability of the tests, including former Theranos employees who took their concerns to federal regulators. Ms. Holmes defended the company publicly, especially after articles last year in The Wall Street Journal enumerated those concerns.
Still, federal inspectors found deficiencies in the Newark plant that could lead to inaccurate results, including inadequately trained employees and samples stored at the wrong temperature. Theranos promised to overhaul the plant and bring in a new slate of experts to fix its problems. Then, in April, Theranos said it was under criminal investigation from the United States Justice Department and disclosed another inquiry from the Securities and Exchange Commission.
As the scrutiny mounted, Theranos faced a cascade of problems. The company’s chief operating officer resigned and its alliance with Walgreens fell apart.
The sanctions disclosed on Thursday were leveled by the Centers for Medicare and Medicaid Services, an arm of the United States Department of Health and Human Services that regulates laboratory testing performed on humans.
In its statement, Theranos said it would shut down and rebuild its Newark lab “from the ground up” and bolster its personnel and training there. Theranos said it would stop patient testing at the Newark facility immediately, before the sanctions take effect in 60 days. The company will continue to offer services through its lab in Arizona, it said.
The company was “disappointed” with the decision, Ms. Holmes said in the statement, adding that Theranos was committed “to demonstrating our dedication to the highest standards of quality and compliance.”
Thank you for your vote of confidence in Apple. I just have found that suppliers can sometimes give some good insight into planned production numbers, and compare that to what a company states or quotes...Just found this message board/site recently and I wanted to try and benefit from others research.
"Wasn't many of the instances from suppliers?"
Yes, that is what I remember reading too. Employees are not the suppliers of produce and meat. We need to get at the source of the problem to solve it/them. I would hope that every restaurant/grocery store reminds employees to wash their hands after going the bathroom and right before they handle food.
So what has been done by this company to identify everywhere the E. Coli came from? Why don't they bring in some outside scientist or expert witness in E. Coli to go visit their suppliers and see everywhere the E. Coli was coming from, then maybe customers and we investors will feel comfortable or safe with our investments.
I did a search on another Colorado based company who has partnered with Hudson Robotics (who I am very familiar with) and came up with quite a few links to their research on E. Coli:
http://www.bing.com/search?q=e.+coli+vaccine+genethera&form=PRNWSB&mkt=en-us&refig=5098d55a8e4247a3ade4c6c8c2b73091&pq=e.+coli+vaccine+genethera&sc=0-19&sp=-1&qs=n&sk=
There is even a youtube video of some doctor that works for this company being interviewed by channel 4 in Denver:
Any updated quotes from Tim Cook or company spokespersons? That press release was just from yesterday, but includes a quote from 2013? I am not worried, but timely communication might help investor confidence!
Apple's Slowing iPhone Sales Take Bite Out of Suppliers' Revenue
TAIPEI--Companies that make parts for Apple Inc. are warning of lower first-half revenues, in a sign of slowing sales of the latest iPhones.
Taiwan Semiconductor Manufacturing Co., which manufactures the chips that run iPhones and other popular electronic devices, forecast Thursday its first-quarter revenue would decline by as much as 10.8% from the previous year, citing demand weakness for high-end smartphones.
Apple components contribute 20% of sales for TSMC, the world's largest contract chip maker, according to a Credit Suisse report...
A spokeswoman for Apple referred to comments made by Apple Chief Executive Tim Cook on an earnings call in 2013 during which he said it was difficult to accurately extrapolate business outlooks from individual data points in the supply chain.
"There's just an inordinately long list of things that would make any single data point not a great proxy for what's going on," he said at the time.
Janice,
This also has me concerned from one of the latest lawsuits: "The Complaint alleges that throughout the Class Period, defendants made materially false and misleading statements regarding the Company's business, operational and compliance policies. Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (i) Chipotle's quality controls were not in compliance with applicable consumer and workplace safety regulations; (ii) Chipotle's quality controls were inadequate to safeguard consumer and employee health; and (iii) as a result of the foregoing, Chipotle's public statements were materially false and misleading at all relevant times.
During the week of August 18, 2015, approximately 100 customers and employees of a Chipotle restaurant in Simi Valley, California became ill. The Ventura County Environmental Health Division reported on September 4, 2015, that the illness was a norovirus outbreak. Health inspectors said that the Chipotle restaurant in question contained dirty and inoperative equipment, equipment directly linked to the sewer, and other sanitary and health violations.
In a similar case, between August 19 and September 3, 2015, about 64 people became sick from a Minnesota Chipotle. The Minnesota Department of Health reported on September 17, 2015, that the illness was salmonella, linked to tomatoes consumed at 22 Chipotle locations. The affected restaurants changed tomato suppliers but did not close their stores.
Additionally, Chipotle closed all of its restaurants in Portland, Oregon and Seattle, Washington, around November 1, 2015, following reports of approximately 20 cases of E. coli by Chipotle patrons. Following this news, Chipotle stock fell $16.23, or approximately 2.5%, to close at $624.00 on November 2, 2015.
In another situation, more than 140 Boston College students fell ill after dining at a Chipotle restaurant in Brighton, Massachusetts around December 2, 2015. Health officials confirmed on December 9, 2015, that the students had contracted norovirus. Following this news, between December 1 and December 9, 2015, Chipotle stock fell $32.73, or 5.6%, to close at $548.01 on December 9, 2015.
On January 6, 2016, pre-market, Chipotle announced that it was served in December 2015 with a federal subpoena, requiring the Company to produce extensive documents following the August 2014's criminal investigation of the dangerous norovirus outbreak in Simi Valley, California. Chipotle said in a filing with the Securities and Exchange Commission that the investigation is being conducted by the U.S. Attorney's Office for the Central District of California in conjunction with the Food and Drug Administration's Office of Criminal Investigations. Following this news, Chipotle stock fell $22.36, or 4.98%, to close at $426.67 on January 6, 2016."
"E-Coli" is serious, remember what it did to Jack in the Box?
I was just thinking about your reply about Hudson Robotics and Dr. Milicci "establishing relationships"...It sure looks like someone with his expertise and experience in food safety could help another Colorado company turn around their major problems, especially now that the U.S Attorney's Office from California and the U.S. Food and Drug Administration's office of criminal investigations have served subpoenas, according to USA Today...all because of their outbreaks of E-coli. Didn't I read in an old SEC Filing that this company did a lot of research on E-coli and helped some university work on a vaccine? Well get the Doctor on Chipotle's Board and then maybe they will help fund this company as a good investment OR for just the public relations benefit of showing that they really do care about "food safety". What do others think about this?
I just saw this press release. Hopefully his experience can make a real difference here at Acadia...anyone else have opinions on the potential of ACAD longterm? TIA
"“Jim brings extensive commercial experience to our Board as we continue our transition to an integrated pharmaceutical company,” said Leslie L. Iversen, Ph.D., Chairman of ACADIA’s Board of Directors. “Over the course of his career, Jim has successfully launched and commercialized major products in multiple therapeutic areas and built market-leading global franchises. His deep knowledge and expertise are welcome as we deliver on our vision of building a leading CNS company dedicated to improving the lives of patients through innovative medicines.”
Mr. Daly previously served as Executive Vice President and Chief Commercial Officer at Incyte Corporation from 2012 to 2015. During his tenure, he was instrumental in re-accelerating the launch of Jakafi® and driving sustained growth. Prior to joining Incyte, Mr. Daly worked for Amgen, Inc. for ten years, holding multiple leadership positions. In his last role, Mr. Daly served as Senior Vice President, North America Commercial Operations, Global Marketing and Commercial Development. Previously, he served as Vice President and General Manager of Amgen’s Oncology Business Unit. His teams at Amgen were responsible for the successful launch of many products, including Aranesp®, Neulasta®, Vectibix®, Nplate®, Xgeva® and Prolia®.
Previously, Mr. Daly spent over 16 years with Glaxo Wellcome/GlaxoSmithKline (GSK) where he held roles of increasing responsibility, including Senior Vice President, General Manager, Respiratory and Anti-Infective Business Unit, and led the U.S. launch of Advair®. He currently serves on the Board of Directors of Chimerix Inc. Mr. Daly earned his B.S. in Pharmacy and M.B.A. from the University at Buffalo, The State University of New York.
New Board of Director with applicable experience imo.
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that Daniel Soland has joined its Board of Directors. Mr. Soland is a seasoned pharmaceutical executive with over 30 years of experience in the biopharmaceutical industry.
“Dan brings a tremendous wealth of commercial experience to the Board and his perspective and insight will be welcomed as ACADIA advances NUPLAZID™ towards registration and prepares for the planned launch of NUPLAZID in the United States,” said Leslie L. Iversen, Ph.D., Chairman of ACADIA’s Board of Directors. “In addition to his extensive commercial experience in launching new drugs and life cycle management, he has led manufacturing and quality organizations and has been instrumental in driving growth in the companies he has served.”
Mr. Soland previously served as Senior Vice President and Chief Operating Officer of ViroPharma starting in 2008 until it was acquired in 2014, and as Vice President and Chief Commercial Officer of the Company from 2006 to 2008. During his tenure at ViroPharma, Mr. Soland managed the commercial, manufacturing and quality organizations, helped build the company’s commercial infrastructure in the United States, Europe, and Canada and led the launch of Cinryze®, one of the most successful ultra-orphan drugs in the United States. Mr. Soland served as President, Chiron Vaccines, of Chiron Corporation from 2005 to 2006 and led the growth of the vaccine business to over $1 billion in sales. From 2002 through 2005, Mr. Soland served as President and Chief Executive Officer of Epigenesis Pharmaceuticals. Earlier in his career, Mr. Soland worked for GlaxoSmithKline in increasing roles of responsibility from 1993 to 2002, including as Vice President and Director, Worldwide Marketing Operations, GSK Biologicals. He currently serves on the board of directors of Tarsa Therapeutics and DBV Technologies SA. Mr. Soland earned his B.S. in Pharmacy from the University of Iowa.
seems reasonable looking at other competitors stock price in this industry...
I know about Hudson Robotics. They are well respected: http://www.hudsonrobotics.com/news/press-release/ but what exactly do they hope to gain from a partnership with Genethera?
I read the press release about Genethera being concerned with milk and formula having a potential link to crohns disease, which is a serious concern for a lot of people, but who do they hope to get for customers to pay for this testing?
Looking at the price of their competitors stock price: http://finance.yahoo.com/q/co?s=ACAD+Competitors your prediction(s) look feasible.
They should 8K it.
I agree with you.